In vitro combination of tigecycline with other antibiotics in Stenotrophomonas maltophilia isolates
In vitro combination of tigecycline with other antibiotics in Stenotrophomonas maltophilia isolates
Background/aim: The aim of this study was to determine the usefulness of tigecycline in combination treatment of Stenotrophomonasmaltophilia infections by evaluating the in vitro synergistic effects of tigecycline with various antibiotics using the E-test method.Materials and methods: Synergy testing by E-test was performed with various antibiotic combinations in 10 S. maltophilia isolatesidentified as a cause of infection. The antibiotics used in the study included tigecycline (TGC), cefoperazone-sulbactam (CPS),ceftazidime (TZ), levofloxacin (LEV), and trimethoprim-sulfamethoxazole (cotrimoxazole) (TS). Four different combinations (TGCCPS, TGC-TZ, TGC-LEV, TGC-TS) were studied with the E-test synergy method.Results: S. maltophilia isolates were found to have the highest level of susceptibility to trimethoprim-sulfamethoxazole, tigecycline, andlevofloxacin. The fractional inhibitory concentration (FIC) index was calculated as FIC = MICAB/MICA + MICBA/MICB. The FICindex values were calculated and classified as synergistic (FIC < 0.5), additive (FIC = 0.5–1), indifferent (FIC = 1–4), and antagonistic(FIC > 4). According to FIC index values, synergy was found with the highest rate with TGC-CPS and TGC-LEV combinations (20%).Antagonistic activity was not found in any combination.Conclusion: When trimethoprim-sulfamethoxazole cannot be used because of resistance or allergy, tigecycline alone or in combinationmay be included as an alternative option. Although in vitro results are promising, clinical data are required.
___
- 1. Senol E. Stenotrophomonas maltophilia: the significance and
role as a nosocomial pathogen. J Hosp Infect 2004; 57: 1-7.
- 2. Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections
caused by Stenotrophomonas maltophilia with particular
attention to resistance mechanisms and therapeutic options.
Front Microbiol 2015; 6: 893.
- 3. Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI,
Kapaskelis AM, Dimopoulos G. Attributable mortality of
Stenotrophomonas maltophilia infections: a systematic review
of the literature. Future Microbiol 2009; 4: 1103-1109.
- 4. Alonso A, Martinez JL. Multiple antibiotic resistance in
Stenotrophomonas maltophilia. Antimicrob Agents Chemother
1997; 41: 1140-1142.
- 5. Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in
Stenotrophomonas maltophilia: involvement of a multidrug
efflux system. Antimicrob Agents Chemother 2000; 44: 287-
293.
- 6. Looney WJ, Narita M, Muhlemann K. Stenotrophomonas
maltophilia: an emerging opportunist human pathogen. Lancet
Infect Dis 2009; 9: 312-323.
- 7. Mendoza DL, Michael D, Waterer GW, Wunderink RG. Update
on Stenotrophomonas maltophilia infection in the ICU. Clin
Pulm Med 2007; 14: 17-22.
- 8. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh
TR. Global emergence of trimethoprim/sulfamethoxazole
resistance in Stenotrophomonas maltophilia mediated by
acquisition of sul genes. Emerg Infect Dis 2007; 13: 559-565.
- 9. Bonfiglio G, Cascone C, Azzarelli C, Cafiso V, Marchetti F,
Stefani S. Levofloxacin in vitro activity and time-kill evaluation
of Stenotrophomonas maltophilia clinical isolates. J Antimicrob
Chemother 2000; 45: 115-117.
- 10. Galles AC, Jones RN, Sader HS. Antimicrobial susceptibility
profile of contemporary clinical strains of Stenotrophomonas
maltophilia isolates: can moxifloxacin activity be predicted by
levofloxacin MIC results? J Chemother 2008; 20: 38-42.
- 11. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh
PR. Therapeutic options for Stenotrophomonas maltophilia
infections beyond co-trimoxazole: a systematic review. J
Antimicrob Chemother 2008; 62: 889-894.
- 12. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de
Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R et
al. Safety and efficacy of intravenous tigecycline in treatment
of community-acquired pneumonia: results from a doubleblind randomized phase 3 comparison study with levofloxacin.
Diagn Microbiol Infect Dis 2009; 63: 52-61.
- 13. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities
of a worldwide collection of Stenotrophomonas maltophilia
isolates tested against tigecycline and agents commonly used
for S. maltophilia infections. Antimicrob Agents Chemother
2010; 54: 2735-2737.
- 14. Clinical and Laboratory Standards Institute. Performance
Standards for Antimicrobial Susceptibility Testing; TwentySecond Informational Supplement. CLSI Document M100-S23.
Wayne, PA, USA: Clinical and Laboratory Standards Institute;
2012.
- 15. Wyeth Pharmaceuticals. Tygacil (Tigecycline) for
Injection [Package Insert]. Philadelphia, PA, USA: Wyeth
Pharmaceuticals Inc.; 2005.
- 16. Chung HS, Hong SG, Kim YR, Shin KS, Whang DH, Ahn
JY, Park YJ, Uh Y, Chang CL, Shin JH et al. Antimicrobial
susceptibility of Stenotrophomonas maltophilia isolates from
Korea, and the activity of antimicrobial combinations against
the isolates. J Korean Med Sci 2013; 28: 62-66.
- 17. Zelenitsky SA, Iacovides H, Ariano RE, Harding GK. Antibiotic
combinations significantly more active than monotherapy in
an in vitro infection model of Stenotrophomonas maltophilia.
Diagn Microbiol Infect Dis 2005; 51: 39-43.
- 18. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial
activity of tigecycline tested against nosocomial bacterial
pathogens from patients hospitalized in the intensive care unit.
Diagn Microbiol Infect Dis 2005; 52: 202-208.
- 19. Insa R, Cercenado E, Goyanes MJ, Morente A. Bouza E. In vitro
activity of tigecycline against clinical isolates of Acinetobacter
baumannii and Stenotrophomonas maltophilia. J Antimicrob
Chemother 2007; 59: 583-585.
- 20. Church D, Lloyd T, Peirano G, Pitout J. Antimicrobial
susceptibility and combination testing of invasive
Stenotrophomonas maltophilia isolates. Scand J Infect Dis 2013;
45: 265-270.
- 21. Wei C, Ni W, Cai X, Zhao J, Cui J. Evaluation of trimethoprim/
sulfamethoxazole (SXT), minocycline, tigecycline,
moxifloxacin, and ceftazidime alone and in combinations
for SXT-susceptible and SXT-resistant Stenotrophomonas
maltophilia by in vitro time-kill experiments. PLoS One 2016;
11: e0152132.
- 22. Nicodemo AC, Paez JI. Antimicrobial therapy for
Stenotrophomonas maltophilia infections. Eur J Clin Microbiol
Infect 2007; 26: 229-237.
- 23. Tekce YT, Erbay A, Cabadak H, Sen S. Tigecycline as a
therapeutic option in Stenotrophomonas maltophilia infections.
J Chemother 2012; 24: 150-154.
- 24. Belvisi V, Fabietti P, del Borgo C, Marocco R, di Vincenzo
E, Soscia F, Mastroianni CM. Successful treatment of
Stenotrophomonas maltophilia soft tissue infection with
tigecycline: a case report. J Chemother 2009; 21: 367-368.
- 25. Blanquer D, de Otero J, Padilla E, Gomez F, Mayol A, Irigaray
R, Espejo P, Rada MA, Makrantoni G, Perez AR. Tigecycline
for treatment of nosocomial acquired pneumonia possibly
caused by multi-drug resistant strains of Stenotrophomonas
maltophilia. J Chemother 2008; 20: 761-763.
- 26. Wu Y, Shao Z. High-dosage tigecycline for Stenotrophomonas
maltophilia bacteremia. Chin Med J 2014; 127: 3199.